EMVCO
19.10.2018 11:02:10 CEST | Business Wire | Press release
EMVCo has today published a draft of its EMV® Secure Remote Commerce (SRC) Specification, which is available for download from the EMVCo website and open for a public comment period of 45 days, until Monday 3 December. The global technical body has made the decision to release a draft specification - EMV SRC Specification v0.9 – before finalising the specification to allow as many payment industry participants as possible, including merchants, card issuers and payment networks, the opportunity to review and contribute to v1.0 which will be published in 2019.
The draft EMV SRC Specification provides a foundation that will enable the processing of e-commerce transactions in a consistent, streamlined fashion across a variety of digital channels and devices, including smartphones, tablets, PCs and other connected devices.
When finalised, it is expected that v1.0 of the EMV SRC Specification will:
- Define interfaces to allow for secure exchanges of payment data across participants in the digital commerce environment.
- Accommodate options for using dynamic data, such as cryptograms or other transaction unique data, to enhance the security of payment transactions on a merchant’s SRC enabled website, mobile app or other e-commerce platform.
- Enable compatibility with other technologies such as EMV Payment Tokenisation and EMV 3-D Secure.
- Facilitate consumer recognition of a common user experience, indicated by an SRC Mark, which conveys to a consumer that a merchant’s e-commerce environment is enabled for EMV SRC.
Stephanie Ericksen, Chair of EMVCo’s Executive Committee, comments: “EMVCo recognises the need to expediently deliver its EMV SRC Specification to help address rising fraud levels in global e-commerce while reducing consumer friction during online checkout.
“Given the high levels of industry interest in the EMV SRC initiative, EMVCo is publishing a draft specification for wider comment before releasing the official 1.0 version. This allows us to expand on the feedback received to date from EMVCo Associates and Subscribers on the specification development, to help ensure that the EMV SRC Specification addresses the needs of stakeholders across the industry.”
Merchants, card issuers, payment networks, consumers and other stakeholders will benefit from participation in the SRC ecosystem. Consumers will be provided with a choice of payment options and a more consistent, secure purchase experience across merchants that choose to adopt an SRC solution. The reduced need for entering card and shipping information has the potential to lower shopping cart abandonment for merchants. SRC participants will also benefit from a simplified integration, thanks to the definition of consistent communications and interfaces across the digital commerce environment.
EMVCo outlines the following process for feedback submission and consideration by EMVCo:
- All interested stakeholders are invited to submit feedback on EMV SRC Specification v0.9 within the 45 day public comment period, ending on Monday 3 December.
- The draft EMV SRC Specification can be found on the EMVCo website .
- Feedback submissions can be made via the public queries mechanism on the EMVCo website .
- Feedback can be made privately or publicly via an option on the EMVCo website. EMVCo will review comments and publish its responses to public comments received. A plan will be established to incorporate applicable recommendations that will help facilitate global interoperability as the EMV SRC Specification evolves.
EMVCo encourages new participants who are interested in contributing to EMV initiatives to join the EMVCo Associates Programme or become an EMVCo Subscriber.
EMV® SRC Specification v1.0 will be published in 2019 and made available for royalty-free download from EMVCo’s website by all interested parties.
– ENDS –
Notes to Editors:
EMV® is a registered trademark in the U.S. and other countries and an unregistered trademark elsewhere. The EMV trademark is owned by EMVCo, LLC.
About EMVCo:
EMVCo is the global technical body that facilitates the worldwide interoperability and acceptance of secure payment transactions by managing and evolving the EMV Specifications and related testing processes. EMV is a technology toolbox that enables globally interoperable secure payments across face-to-face and remote environments. Adoption of EMV Specifications and associated approval and certification processes promotes a unified international payments framework, which supports an advancing range of payment methods, technologies and acceptance environments. The specifications are available royalty free, designed to be flexible, and can be adapted regionally to meet national payment requirements and accommodate local regulations.
EMVCo is collectively owned by American Express, Discover, JCB, Mastercard, UnionPay and Visa, and focuses on the technical advancement of the EMV Specifications. To provide all payment stakeholders with a platform to engage in its strategic and technical direction, EMVCo operates an Associates Programme and encourages all interested parties to get involved.
Visit www.emvco.com for further information and join EMVCo on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181019005154/en/
Contact:
For EMVCo media Dave Amos, +44 113 3501922 david@iseepr.co.uk or Andrew Peacock, +44 113 3501922 andrew@iseepr.co.uk
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom